10:27 AM EST - Eupraxia Pharmaceuticals Inc. : Announced that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of EP-104IAR in the treatment of adults with osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc.
shares T.EPRX are trading up $0.58 at $7.75.
